摘要
目的:比较复方利福平胶囊与普通四联制剂中主要成分利福平在犬体内的相对生物利用度。方法:采用双周期随机交叉试验,多剂量给予犬复方利福平胶囊与普通四联制剂,用HPLC法测定血浆中利福平的浓度,计算相对生物利用度。结果:利福平胶囊和普通四联制剂中利福平的Cmax为(54.09±13.86)和(52.33±12.78)mg·L-1;Cmin为(14.50±5.24)和(12.70±4.14)mg·L-1;Tmax为(4.67±1.37)和(3.83±1.17)h;Cav为(30.07±6.42)和(30.04±9.09)mg·L-1;AUCss为(721.63±154.13)和(721.01±218.04)mg·h-1·L-1;DF为(137.06±61.12)和(134.61±22.07)％;F为(108.54±35.21)％。利福平微丸胶囊中的利福平Tmax大于普通四联制剂,经t检验P<0.05,表明利福平微丸胶囊中的利福平比普通四联制剂达峰慢。结论:两种制剂中的利福平生物等效。
Objective: To study the relative bioavailability of rifampicin of compound rifampicin capsule in dogs. Methods: Several oral administrations of compound rifampicin capsule and common four unite preparation to 6 dogs in a randomized cross-over study. The plasma concentration of rifampicin was determined buy HPLC. Results: The pharmacokinetic parameters of test and reference preparation for rifampicin were as follews: C (54.09±13.86)mg . L and (52.33± 12.78) mg . L,C min(14.50±5.24) and (12.70±4.14) mg . L,Tmin (4.67± 1.37) h and(3.83 ± 1.17) h, Cav:(30.07± 6.42)mg. L and ( 30.04±9.09) mg . L , AUC :(721.63±154.13)mg . h . L and ( 721.01 ± 218.04) mg . h . L, DF (137.06±61.12)%and (134.61 ± 22.07) %,F: (108.54±35.21) %. Conclusion: The two preparations were bioequivalent.
出处
《抗感染药学》
2004年第1期19-20,共2页
Anti-infection Pharmacy
